Integrative cBioPortal Analysis Revealed Molecular Mechanisms That Regulate EGFR-PI3K-AKT-mTOR Pathway in Diffuse Gliomas of the Brain

Cancers, Journal Year: 2021, Volume and Issue: 13(13), P. 3247 - 3247

Published: June 29, 2021

Diffuse gliomas are a heterogeneous group of tumors with aggressive biological behavior and lack effective treatment methods. Despite new molecular findings, the differences between pathohistological types still require better understanding. In this in silico analysis, we investigated AKT1, AKT2, AKT3, CHUK, GSK3β, EGFR, PTEN, PIK3AP1 as participants EGFR-PI3K-AKT-mTOR signaling using data from publicly available cBioPortal platform. Integrative large-scale analyses changes copy number aberrations (CNA), methylation, mRNA transcription protein expression within 751 samples diffuse astrocytomas, anaplastic astrocytomas glioblastomas. The study showed significant percentage CNA PTEN (76%), CHUK (75% each), EGFR (74%), AKT2 (39%), AKT1 (32%), AKT3 (19%) GSK3β (18%) total sample. Comprehensive statistical show how genomics epigenomics affect examined genes differently across various grades, suggesting that behave like tumor suppressors, while oncogenic involved enhanced activity pathway. Our findings contribute to knowledge ultimately offer possibility targets personalized therapies patients gliomas.

Language: Английский

---

Valproic Acid: A Promising Therapeutic Agent in Glioma Treatment

Frontiers in Oncology, Journal Year: 2021, Volume and Issue: 11

Published: Sept. 10, 2021

Glioma, characterized by infiltrative growth and treatment resistance, is regarded as the most prevalent intracranial malignant tumor. Due to its poor prognosis, accumulating investigation has been performed for improvement of overall survival (OS) progression-free (PFS) in glioma patients. Valproic acid (VPA), one common histone deacetylase inhibitors (HDACIs), detected directly or synergistically exert inhibitory effects on vitro vivo . In this review, we generalize latest advances VPA treating underlying mechanisms clinical implications, providing a clearer profile application therapeutic agent glioma.

Language: Английский

---

The Roles Played by Long Non-Coding RNAs in Glioma Resistance

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(13), P. 6834 - 6834

Published: June 25, 2021

Glioma originates in the central nervous system and is classified based on both histological features molecular genetic characteristics. Long non-coding RNAs (lncRNAs) are longer than 200 nucleotides known to regulate tumorigenesis tumor progression, even confer therapeutic resistance glioma cells. Since oncogenic lncRNAs have been frequently upregulated promote cell proliferation, migration, invasion cells, while tumor-suppressive responsible for inhibition of apoptosis decrease sensitivity cells generally downregulated, dysregulation affects many patients, expression profiles associated with these needed diagnose disease stage determine suitable strategies. Accumulating studies show that orchestrations result signaling pathways influence pathogenesis progression glioma. Furthermore, several related regulation existing anticancer therapies, including radiotherapy, chemotherapy immunotherapy. Consequently, we undertook this review improve understanding influenced by how affect resistance.

Language: Английский

---

Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy

Molecular Therapy — Oncolytics, Journal Year: 2022, Volume and Issue: 26, P. 314 - 329

Published: July 31, 2022

Language: Английский

---

LncRNAs in colorectal cancer: Biomarkers to therapeutic targets

Clinica Chimica Acta, Journal Year: 2023, Volume and Issue: 543, P. 117305 - 117305

Published: March 1, 2023

Language: Английский

---